Drug Profile
Uridine triacetate
Alternative Names: PN 401; TAU; Triacetyluridine; Vistogard; Vistonuridine; XuridenLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Wellstat Therapeutics Corporation
- Class Antidepressants; Chemoprotectants; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Adenosine triphosphatase stimulants; Mitochondrial protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Orotic aciduria; Poisoning
- No development reported Neurodegenerative disorders
- Discontinued Diabetic neuropathies; Gastric cancer; Pancreatic cancer
Most Recent Events
- 02 Feb 2021 Discontinued - Phase-II for Gastric cancer in USA (PO)
- 02 Feb 2021 Discontinued - Phase-III for Pancreatic cancer in Canada (PO)
- 02 Feb 2021 Discontinued - Phase-III for Pancreatic cancer in USA (PO)